AgomAb Therapeutics NV American Depositary Shares (AGMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AgomAb Therapeutics NV American Depositary Shares (AGMB) has a cash flow conversion efficiency ratio of -0.085x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.44 Million) by net assets ($146.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is AgomAb Therapeutics NV American Deposita worth for the company's overall valuation and market capitalisation.
AgomAb Therapeutics NV American Depositary Shares - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how AgomAb Therapeutics NV American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AgomAb Therapeutics NV American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AgomAb Therapeutics NV American Depositary Shares ranked by their cash flow conversion efficiency. See AgomAb Therapeutics NV American Deposita (AGMB) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Masoval AS
OL:MAS
|
0.159x |
|
Jiangsu Xiuqiang Glasswork Co
SHE:300160
|
0.030x |
|
ZRP Printing Group Co. Ltd.
SHE:301223
|
N/A |
|
Sijin Intelligent Forming Machinery
SHE:003025
|
0.057x |
|
Wam Global Ltd
AU:WGB
|
0.044x |
|
Zhejiang Kanglongda Special
SHG:603665
|
0.024x |
|
Shanghai National Center of Testing and Inspection for Electric Cable and Wire Co. Ltd.
SHE:301289
|
-0.003x |
|
Concord International Securities Co Ltd
TWO:5864
|
-0.119x |
Annual Cash Flow Conversion Efficiency for AgomAb Therapeutics NV American Depositary Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of AgomAb Therapeutics NV American Depositary Shares from 2022 to 2025. View AgomAb Therapeutics NV American Deposita (AGMB) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.90 Million | $-51.74 Million | -0.395x | -58.76% |
| 2024-12-31 | $188.08 Million | $-46.83 Million | -0.249x | -53.32% |
| 2023-12-31 | $151.44 Million | $-24.59 Million | -0.162x | +43.28% |
| 2022-12-31 | $66.25 Million | $-18.97 Million | -0.286x | -- |
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinica… Read more